FOLFiRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab for Patients   with Advanced or Metastatic Adenocarcinoma of The Stomach or   Gastroesophageal Junction As Second-Line Therapy - Interim Safety and   Efficacy Results from The Phase II Ramiris Study (AIO-STO-0415) of the   German Gastric Group at AIO

Title:: FOLFiRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab for Patients with Advanced or Metastatic Adenocarcinoma of The Stomach or Gastroesophageal Junction As Second-Line Therapy - Interim Safety and Efficacy Results from The Phase II Ramiris Study (AIO-STO-0415) of the German Gastric Group at AIO
Document type:: Meeting Abstract
Author(s):: Lorenzen, Sylvie; Thuss-Patience, Peter; Pauligk, Claudia; Goekkurt, Eray; Ettrich, Thomas J.; Lordick, Florian; Stahl, Michael; Reichardt, Peter; Soekler, Martin; Pink, Daniel; Probst, Stephan; Alguel, Nana; Hinke, Axel; Goetze, Thorsten; Al-Batran, Salah-Eddin
Journal title abbreviation:: Oncology Research and Treatment
Year:: 2020
Journal volume:: 43 Suppl 1
Pages contribution:: 58-58
Print-ISSN:: 2296-5270
TUM Institution:: III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
BibTeX

Occurrences: